Key Details
Price
$48.47Annual ROE
222.07%Beta
0.89Events Calendar
Next earnings date:
Feb 20, 2025Recent quarterly earnings:
Oct 31, 2024Recent annual earnings:
Feb 20, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Halozyme Therapeutics (HALO) is likely to do better than the market because it shows strong financial growth.
Investors focusing on the Medical - Biomedical and Genetics sector may be familiar with Halozyme Therapeutics (HALO) and Amicus Therapeutics (FOLD). However, which of these two companies offers the better choice for those seeking undervalued stocks?
Wall Street analysts have set an average price target for Halozyme Therapeutics (HALO) that suggests a possible increase of 27.1%. Although the reliability of this popular measure is debatable, the recent positive changes in earnings estimates could lead to a rise in the stock's value.
The Zacks Style Scores help investors quickly identify highly-rated stocks that match their investment preferences. Here are some reasons to make the most of this tool.
The Zacks Style Scores help investors quickly identify highly-rated stocks that match their investment preferences. Here are some reasons why you should make use of this tool.
At Zacks, we concentrate on the reliable Zacks Rank system, which highlights earnings estimates and changes in those estimates to identify excellent stocks. At the same time, we keep an eye on the most recent trends in value, growth, and momentum to support our top selections.
Halozyme Therapeutics (HALO) has strong growth characteristics that may enable it to significantly exceed market performance.
This is a comparison of how Halozyme Therapeutics (HALO) and Addus HomeCare (ADUS) have done in relation to their industry this year.
Investors looking at Medical - Biomedical and Genetics stocks probably know about Halozyme Therapeutics (HALO) and Amicus Therapeutics (FOLD). However, which of these two stocks is more appealing for value investors?
SAN DIEGO, Nov. 27, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) has announced that its executive team will present and hold investor meetings at upcoming conferences. The details include a presentation by Chief Financial Officer Nicole LaBrosse at the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024, at 10:30am PT in New York, and another by President and CEO Helen Torley at the 7th Annual Evercore ISI HealthCONx Conference on the same day at 9:30am PT in Miami. A live audio webcast of these presentations will be accessible in the Investor Relations section of the company's website.
FAQ
- What is the primary business of Halozyme Therapeutics?
- What is the ticker symbol for Halozyme Therapeutics?
- Does Halozyme Therapeutics pay dividends?
- What sector is Halozyme Therapeutics in?
- What industry is Halozyme Therapeutics in?
- What country is Halozyme Therapeutics based in?
- When did Halozyme Therapeutics go public?
- Is Halozyme Therapeutics in the S&P 500?
- Is Halozyme Therapeutics in the NASDAQ 100?
- Is Halozyme Therapeutics in the Dow Jones?
- When was Halozyme Therapeutics's last earnings report?
- When does Halozyme Therapeutics report earnings?
- Should I buy Halozyme Therapeutics stock now?